Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By End User; By Region; Segment Forecast, 2024

Description

List of Tables

The global pneumococcal vaccine market size is expected to reach USD 14.43 billion by 2032, according to a new study by Polaris Market Research. The report "Pneumococcal Vaccine Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The pneumococcal vaccine market is experiencing significant growth driven by increased awareness about pneumococcal infections and the expansion of government-sponsored immunization programs. As public health campaigns highlight the dangers of pneumococcal disease, including pneumonia and meningitis, individuals and healthcare providers are more inclined to seek vaccination. Additionally, governments worldwide are implementing robust immunization initiatives aimed at enhancing community health and reducing healthcare costs associated with pneumococcal diseases. These programs often include subsidies and educational resources, making vaccines more accessible to underserved populations. As awareness continues to rise and vaccination efforts intensify, the demand for pneumococcal vaccines is expected to increase substantially, impacting the pneumococcal vaccine market growth positively.

The pneumococcal vaccine market is driven by government initiatives and health policies that promote widespread vaccination. These programs aim to enhance public health by reducing the incidence of pneumococcal diseases, such as pneumonia and meningitis. As governments implement comprehensive immunization strategies, including funding and awareness campaigns, accessibility to vaccines improves, leading to higher vaccination rates.

Increasing partnerships between biotech firms and market players aimed at developing more effective pneumococcal conjugate vaccines (PCVs) are fueling the pneumococcal vaccine market growth in forecast years. For Instance, in June 2023, SK Bioscience collaborated with Sanofi to create GBP410, a 21-valent PCV that demonstrated positive results in Phase 2 studies involving toddlers and infants. Similarly, in March 2024, Pfizer's PREVENAR 20, a 20-valent PCV, received approval from the European Commission to immunize infants, children, and adolescents across Europe and globally. These strategic alliances enhance research capabilities, expedite development timelines, and expand vaccine access, ultimately driving market growth during projected years.

Pneumococcal Vaccine Market Report Highlights

The pneumococcal polysaccharide vaccine (PPV) segment accounted for the largest market share in 2023 primarily due to global acceptance and easy availability.

The Pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, as PCV covers more range of the streptococcus pneumoniae.

The Prevnar 13 segment accounted for the largest market share in 2023, as it caters to a wider range of age, and is more efficient in treating the disease.

The Asia Pacific is projected to register the fastest growth over the study period, attributable to the increasing investment in pneumococcal vaccine development.

The global players are GSK plc, Pfizer Inc, Merck, Serum Institute, CSL Ltd., and Sanofi.

Polaris Market Research has segmented the pneumococcal vaccine market report based on vaccine type, product type, distribution channel, and region:

By Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

Pneumococcal conjugate vaccine (PCV)
Pneumococcal polysaccharide vaccine (PPV)

By Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

Prevnar 13
Synflorix
Pneumovax23

By Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Distribution partner companies
Non-governmental Organizations
Government Authorities

By Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa

Product Code: PM5107

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Vaccine Types
- 3.2.1. Primary Vaccine Types
- 3.2.2. Secondary Vaccine Types

4. Global Pneumococcal Vaccine Market Insights

4.1. Pneumococcal Vaccine Market - Market Snapshot
4.2. Pneumococcal Vaccine Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Incidence of Pneumococcal Disease Across All Age Groups is Driving Market Growth
  - 4.2.1.2. Health Policies Promoting Widespread Vaccination is Propelling Market Size
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Regulatory Hurdles
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Pneumococcal Vaccine Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Pneumococcal Vaccine Market, by Vaccine Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
5.3. Pneumococcal conjugate vaccine
- 5.3.1. Global Pneumococcal Vaccine Market, by Pneumococcal conjugate vaccine, by Region, 2019-2032 (USD billion)
5.4. Pneumococcal polysaccharide vaccine
- 5.4.1. Global Pneumococcal Vaccine Market, by Pneumococcal polysaccharide vaccine, by Region, 2019-2032 (USD billion)

6. Global Pneumococcal Vaccine Market, by Product

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
6.3. Prevnar 13
- 6.3.1. Global Pneumococcal Vaccine Market, by Prevnar 13, by Region, 2019-2032 (USD billion)
6.4. Synflorix
- 6.4.1. Global Pneumococcal Vaccine Market, by Synflorix, by Region, 2019-2032 (USD billion)
6.5. Pneumovax23
- 6.5.1. Global Pneumococcal Vaccine Market, by Pneumovax23, by Region, 2019-2032 (USD billion)
6.6. Other Product
- 6.6.1. Global Pneumococcal Vaccine Market, by Other Product, by Region, 2019-2032 (USD billion)

7. Global Pneumococcal Vaccine Market, by End User

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
7.3. Public Sector
- 7.3.1. Global Pneumococcal Vaccine Market, by Public Sector, by Region, 2019-2032 (USD billion)
7.4. Private Sector
- 7.4.1. Global Pneumococcal Vaccine Market, by Private Sector, by Region, 2019-2032 (USD billion)

8. Global Pneumococcal Vaccine Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
8.3. Pneumococcal Vaccine Market - North America
- 8.3.1. North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
- 8.3.2. North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
- 8.3.3. North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.3.4. Pneumococcal Vaccine Market - U.S.
  - 8.3.4.1. U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.3.4.2. U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.4.3. U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.3.5. Pneumococcal Vaccine Market - Canada
  - 8.3.5.1. Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.3.5.2. Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.5.3. Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
8.4. Pneumococcal Vaccine Market - Europe
- 8.4.1. Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
- 8.4.2. Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
- 8.4.3. Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.4. Pneumococcal Vaccine Market - UK
  - 8.4.4.1. UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.4.2. UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.4.3. UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.5. Pneumococcal Vaccine Market - France
  - 8.4.5.1. France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.5.2. France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.5.3. France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.6. Pneumococcal Vaccine Market - Germany
  - 8.4.6.1. Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.6.2. Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.6.3. Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.7. Pneumococcal Vaccine Market - Italy
  - 8.4.7.1. Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.7.2. Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.7.3. Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.8. Pneumococcal Vaccine Market - Spain
  - 8.4.8.1. Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.8.2. Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.8.3. Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.9. Pneumococcal Vaccine Market - Netherlands
  - 8.4.9.1. Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.9.2. Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.9.3. Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.10. Pneumococcal Vaccine Market - Russia
  - 8.4.10.1. Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.10.2. Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.10.3. Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.4.11. Pneumococcal Vaccine Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.4.11.2. Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.4.11.3. Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
8.5. Pneumococcal Vaccine Market - Asia Pacific
- 8.5.1. Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
- 8.5.2. Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
- 8.5.3. Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.4. Pneumococcal Vaccine Market - China
  - 8.5.4.1. China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.4.2. China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.4.3. China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.5. Pneumococcal Vaccine Market - India
  - 8.5.5.1. India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.5.2. India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.5.3. India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.6. Pneumococcal Vaccine Market - Malaysia
  - 8.5.6.1. Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.6.2. Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.6.3. Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.7. Pneumococcal Vaccine Market - Japan
  - 8.5.7.1. Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.7.2. Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.7.3. Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.8. Pneumococcal Vaccine Market - Indonesia
  - 8.5.8.1. Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.8.2. Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.8.3. Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.9. Pneumococcal Vaccine Market - South Korea
  - 8.5.9.1. South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.9.2. South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.9.3. South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.10. Pneumococcal Vaccine Market - Australia
  - 8.5.10.1. Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.10.2. Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.10.3. Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.5.11. Pneumococcal Vaccine Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.5.11.2. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.5.11.3. Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
8.6. Pneumococcal Vaccine Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
- 8.6.2. Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
- 8.6.3. Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.6.4. Pneumococcal Vaccine Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.6.4.2. Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.6.4.3. Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.6.5. Pneumococcal Vaccine Market - UAE
  - 8.6.5.1. UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.6.5.2. UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.6.5.3. UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.6.6. Pneumococcal Vaccine Market - Israel
  - 8.6.6.1. Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.6.6.2. Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.6.6.3. Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.6.7. Pneumococcal Vaccine Market - South Africa
  - 8.6.7.1. South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.6.7.2. South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.6.7.3. South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.6.8. Pneumococcal Vaccine Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.6.8.2. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.6.8.3. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
8.7. Pneumococcal Vaccine Market - Latin America
- 8.7.1. Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
- 8.7.2. Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
- 8.7.3. Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.7.4. Pneumococcal Vaccine Market - Mexico
  - 8.7.4.1. Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.7.4.2. Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.7.4.3. Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.7.5. Pneumococcal Vaccine Market - Brazil
  - 8.7.5.1. Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.7.5.2. Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.7.5.3. Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.7.6. Pneumococcal Vaccine Market - Argentina
  - 8.7.6.1. Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.7.6.2. Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.7.6.3. Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
- 8.7.7. Pneumococcal Vaccine Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  - 8.7.7.2. Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.7.7.3. Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. GSK plc
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Pfizer Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Merck KGaA
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Serum Institute of India Pvt. Ltd.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. CSL Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Sanofi S.A
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Walvax Biotechnology Co., Ltd.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Beijing Minhai Biotechnology Co., Ltd
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Johnson & Johnson
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. AstraZeneca
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. Novavax
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development